Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$54.8 million.

  • Protagonist Therapeutics' Net Cash Flow rose 7557.79% to -$54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.3 million, marking a year-over-year increase of 8255.03%. This contributed to the annual value of -$89.5 million for FY2024, which is 24672.61% down from last year.
  • Per Protagonist Therapeutics' latest filing, its Net Cash Flow stood at -$54.8 million for Q3 2025, which was up 7557.79% from $29.0 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Net Cash Flow high stood at $183.1 million for Q2 2024, and its period low was -$224.5 million during Q3 2024.
  • Over the past 5 years, Protagonist Therapeutics' median Net Cash Flow value was -$4.9 million (recorded in 2023), while the average stood at -$189578.9.
  • As far as peak fluctuations go, Protagonist Therapeutics' Net Cash Flow crashed by 452455.2% in 2024, and later skyrocketed by 39948.44% in 2025.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Net Cash Flow stood at $3.1 million in 2021, then tumbled by 975.43% to -$27.1 million in 2022, then crashed by 61.34% to -$43.8 million in 2023, then grew by 22.67% to -$33.9 million in 2024, then plummeted by 61.88% to -$54.8 million in 2025.
  • Its last three reported values are -$54.8 million in Q3 2025, $29.0 million for Q2 2025, and $42.4 million during Q1 2025.